Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2017-11-13 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2017-11-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Senior Vice President and Chief Financial Officer, Michael J. Tomsicek, including his employment agreement and compensation. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The primary focus is on management changes, which aligns with the category for announcements of changes in the company's board of directors or senior management. Therefore, the document fits the 'Board/Management Information' category (MANG). The document length (9537 characters) is sufficient to contain detailed information, not just a brief announcement or a report publication notice. Hence, the classification is MANG with high confidence.
2017-11-13 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by CRISPR Therapeutics AG. It is a detailed registration statement under the Securities Act of 1933 for the offering of securities including common shares, debt securities, warrants, units, and subscription rights. The document includes a prospectus describing the securities, risk factors, company overview, and legal information. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, confirming it is a primary filing of this type.
2017-11-09 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option and incentive plans. It includes details about the registration of additional shares under the CRISPR Therapeutics AG Amended and Restated 2016 Stock Option and Incentive Plan. The document is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 8948 characters, which is substantial and contains the full registration statement, not just an announcement or certification.
2017-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2017, reporting the financial results for the third quarter ended September 30, 2017. It includes a press release as Exhibit 99.1 announcing the financial results. The text explicitly states that the Form 8-K is furnishing the press release and that the information is not "filed" for purposes of Section 18, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3323 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim or quarterly report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2017-11-08 English
10-Q
Interim / Quarterly Report Q3 2017
2017-11-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.